

## **CE Announcement**

**Title** – *Minimizing Dosing Stress During the Pre- and Post-Operative Period*

**Date and Time of CE Activity** – **July 12, 2024**

**Location, including city and state** – **Indianapolis, Indiana**

**Overview** – Minimizing stress in rodents is not only good animal welfare, but also better science. Rodents can experience stress during the post-operative period because of anxiety and fear, direct handling by humans, unrelieved pain and conventional dosing methods. This additional stress can change physiologic function by altering metabolic rate, immune response and post-operative recovery. Minimizing dosing stress can be a significant approach to reducing physiologic stress and hastening post-op recovery. Understanding these low stress dosing concepts is essential when working with the biomedical research community.

**Overall Activity Goal** - The objective of this knowledge-based activity is to teach the audience about low stress dosing options for research animals.

**Target Audience** – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

**Learning Objectives** – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Review the dosing needs of laboratory animals.
2. List available dosing strategies for laboratory animals.

### **Pharmacy Technicians:**

1. Review the dosing needs of laboratory animals.



**Continuing Education Information** – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will

provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-067-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

**NABP e-PROFILE ID NUMBER:** Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

**Full Disclosure Policy Affecting CPE Activities –** As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of

any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Karen Froberg-Fejko

Relevant financial disclosures: None

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals  
Presentation  
Self-Assessment Activities  
Discussion and Questions

## **CE Announcement**

Title – ***GFI #256 on the March***

Date and Time of CE Activity – **July 12, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – The Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) explains circumstances when compounding of approved animal drugs or approved human drugs is permitted but this does not include compounding of animal drugs from active pharmaceutical ingredients. FDA published GFI-256 to explain the circumstances when FDA will use discretionary enforcement when compounding animal drugs from active pharmaceutical ingredients. FDA began inspecting compounding pharmacies to GFI-256 in October 2023 yet many compounding technicians and pharmacists are unaware of the requirements. The purpose of this knowledge-based activity is to review AMDUCA and GFI-256 as well as FDA actions related to animal compounding since October 2023.

Overall Activity Goal - The objective of this knowledge-based activity is to review AMDUCA and GFI-256 as well as FDA actions related to animal compounding since October 2023.

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Explain federal requirements related to the use of bulk drug substances in veterinary compounding.
2. Describe the circumstances when FDA may use enforcement discretion related to the use of bulk drug substances in veterinary compounding.
3. Review recent FDA action related to the use of bulk drug substances in veterinary compounding.

### **Pharmacy Technicians:**

1. Explain federal requirements related to the use of bulk drug substances in veterinary compounding.

2. Describe the circumstances when FDA may use enforcement discretion related to the use of bulk drug substances in veterinary compounding.
3. Review recent FDA action related to the use of bulk drug substances in veterinary compounding.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-068-L/H07-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
 <b>Non-Member Rates</b>	 Early Bird through	 On-Time after May 1, 2024

	May 1, 2024	
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Brenda Jensen

Relevant financial disclosures: Dr. Jensen reported receiving a consulting fee from Compounding Facilities. All financial disclosures have been mitigated by our office.

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and

RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions

## **CE Announcement**

**Title** – *Challenges of Providing Care for Zoo Animals & Pharmacological Challenges in Zoo and Wildlife Medicine*

**Date and Time of CE Activity** – **July 12, 2024**

**Location, including city and state** – **Indianapolis, Indiana**

**Overview** – This on-site lecture will review some of the pharmacological challenges unique to zoo and wildlife medicine. This includes methods of drug administration, limitations due to drug concentration and volume, issues with palatability, and the need for additional pharmacokinetic studies. It will also address the importance of extra-label drug use and compounded medications. The use of extra-label and compounded drugs are vital for veterinarians due to the lack of FDA-approved medications for the large diversity of animal species. Pharmacists are needed to provide these high quality, effective, compounded medications. However, pharmacists may be reluctant to provide these medications due to regulatory concerns and fear of adverse drug reactions or lack of efficacy. However, pharmacists can consult with veterinarians and other medical professionals to address the unique species differences in physiology and drug metabolism in order to provide safe and effective compounded medications for animal patients within the confines of the FDA's regulations as well as state and local laws.

**Overall Activity Goal** - The objective of this knowledge-based activity is to inform the audience of the major challenges zoo and wildlife veterinarians face on a daily basis, including the reliance on extra-label drug use and compounded.

**Target Audience** – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

**Learning Objectives** – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Describe common pharmacological challenges for the zoo and wildlife veterinarian.
2. Describe the benefits of compounded medications for veterinary patients.
3. Describe the potential risks of compounded medications for veterinary patients.
4. Identify regulatory resources for pharmacists interested in compounding veterinary pharmaceuticals.



**Pharmacy Technicians:**

1. Describe common pharmacological challenges for the zoo and wildlife veterinarian.
2. Describe the benefits of compounded medications for veterinary patients.
3. Describe the potential risks of compounded medications for veterinary patients.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit each (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-069-L/H07-P/T & 0064-9999-24-078-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224

<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Michelle Bowman

Relevant financial disclosures: None

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+

macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions

## **CE Announcement**

Title – *Therapy of Immune-mediated Disease in Dogs*

Date and Time of CE Activity – **July 13, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – Immune-mediated diseases in dogs are managed primarily with corticosteroids used at doses which would suppress the immune system. Due to adverse effects associated with high-dose, long-term corticosteroid therapies, a number of adjunctive immune-suppressive agents are used. The indications for and considerations applied when selecting adjunctive therapies is more nuanced and complex depending on various patient and disease related factors. This lecture will present the common immunosuppressive therapies used in dogs along with their indications and contraindications. Additionally, novel immunosuppressive and immunomodulatory therapies will be discussed.

Overall Activity Goal - The objective of this knowledge-based activity is to present an overview of available and emerging immune-suppressive therapies in dogs.

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. List the common adjunctive immune-suppressive medications used in dogs.
2. Describe adverse effects of azathioprine, cyclosporine, mycophenolate, and leflunomide.
3. Recognize clinical scenarios which indicate the addition of an immune suppressive medication.
4. Identify emerging immune-suppressive therapies (frunevetmab, bedinvetmab, fuzapladib sodium).

### **Pharmacy Technicians:**

1. List the common adjunctive immune-suppressive medications used in dogs.

2. Describe adverse effects of azathioprine, cyclosporine, mycophenolate, and leflunomide.
3. Identify emerging immune-suppressive therapies (frunevetmab, bedinvetmab, fuzapladib sodium).



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-070-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

**NABP e-PROFILE ID NUMBER:** Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
 <b>Non-Member Rates</b>	 Early Bird through May 1, 2024	 On-Time after May 1, 2024

1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Andrew Woolcock

Relevant financial disclosures: Dr. Woolcock reported receiving grant funding from Nutramax Laboratories for being the principal investigator. All financial disclosures have been mitigated by our office.

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and

recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions

## **CE Announcement**

Title – *Therapy of Immune-mediated Disease in Cats*

Date and Time of CE Activity – **July 13, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – Immune-mediated diseases in cats are encountered, in general, less frequently than in dogs. Because of this, and other factors, our knowledge about the use of non-steroidal immunosuppressive medications in cats is more limited. Additionally, cats have different enzyme systems and metabolic pathways compared to dogs, so the pharmacokinetics of commonly used immunosuppressive medications are quite different in cats, as are the toxicity profiles. This lecture will present the common immunosuppressive therapies used in cats along with their indications and contraindications.

Overall Activity Goal - The objective of this knowledge-based activity is to present an overview of available and emerging immune-suppressive therapies in cats.

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. List the common adjunctive immune-suppressive medications used in cats.
2. Describe adverse effects of azathioprine, cyclosporine, mycophenolate, and chlorambucil.
3. Recognize clinical scenarios which indicate the addition of an immune suppressive medication.

### **Pharmacy Technicians:**

1. List the common adjunctive immune-suppressive medications used in cats.
2. Describe adverse effects of azathioprine, cyclosporine, mycophenolate, and chlorambucil.





Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-071-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Andrew Woolcock

Relevant financial disclosures: Dr. Woolcock reported receiving grant funding from Nutramax Laboratories for being the principal investigator. All financial disclosures have been mitigated by our office.

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions

## **CE Announcement**

Title – ***Feline Hyperthyroidism***

Date and Time of CE Activity – **July 13, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – Hyperthyroidism is a common endocrinopathy in dogs. Treatment for this condition has historically been medication (methimazole); however, this medication is associated with a few side effects that can necessitate discontinuation. Thus, newer treatment options are available, such as Hill's y/d and radioactive iodine. The purpose of this knowledge-based activity is to review feline hyperthyroidism, with a focus on all treatment options, but particularly Hill's y/d and radioactive iodine therapy.

Overall Activity Goal - The objective of this application-based activity is to review feline hyperthyroidism, with a focus on all treatment options, but particularly Hill's y/d and radioactive iodine therapy.

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Identify common clinical signs (related to hyperthyroidism).
2. Identify physical examination abnormalities related to increase in cardiac output and 'masking' of azotemia.
3. Create a treatment plan for a newly diagnosed hyperthyroid cat.

### **Pharmacy Technicians:**

1. Identify common clinical signs (related to hyperthyroidism).
2. Identify physical examination abnormalities related to increase in cardiac output and 'masking' of azotemia.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-072-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Application

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Tim Bolton

Relevant financial disclosures: None

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions

## **CE Announcement**

Title – *Canine Hypothyroidism*

Date and Time of CE Activity – **July 13, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – Hypothyroidism is a relatively common endocrinopathy in dogs, with an incidence of between 0.8 and 2%. Treatment for this condition involves the daily administration of oral levothyroxine (thyroid hormone supplementation). Historically, oral tablets have been the most commonly administered of the levothyroxine formulations; however, there has been somewhat recent FDA approval of a liquid formulation. An understanding of the differences between the oral tablet and liquid formations is very important when prescribing this medication. The purpose of this knowledge-based activity is to briefly review canine hypothyroidism, with a focus on treatment options (tablets versus liquid levothyroxine).

Overall Activity Goal - The objective of this knowledge-based activity is to briefly review canine hypothyroidism, with a focus on treatment options (tablets versus liquid levothyroxine).

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Identify common and uncommon clinical signs (related to hypothyroidism).
2. Define a treatment plan for a newly diagnosed hypothyroid dog.
3. Describe the common treatment challenges associated with hypothyroidism.

### **Pharmacy Technicians:**

1. Identify common and uncommon clinical signs (related to hypothyroidism).
2. Describe the common treatment challenges associated with hypothyroidism.





Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-073-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Tim Bolton

Relevant financial disclosures: None

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals  
Presentation  
Self-Assessment Activities  
Discussion and Questions

## **CE Announcement**

Title – *Use of SGLT2 inhibitors in cats*

Date and Time of CE Activity – **July 13, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – Pharmacists are asked to fill prescriptions for SGLT2 inhibitors but may not be familiar with the use in veterinary species. The purpose of this lecture is to educate pharmacists about the evidence supporting the use of these drugs in cats. The mechanism of action, indications for, and potential adverse effect of these drugs will be discussed, and recommended monitoring strategies for cats being treated with these drugs will be provided. Case studies will be used to demonstrate their application. Troubleshooting guidance will be provided during the lecture and contraindications to use discussed.

Overall Activity Goal - The objective of this knowledge-based activity is to educate pharmacists and pharmacy technicians about the indications for treatment with SGLT2 inhibitors in diabetic cats.

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Explain the mechanism of action of SGLT2 inhibitors in treatment of cats with type 2 diabetes mellitus.
2. Identify specific SGLT2 inhibitors that have been adequately evaluated in veterinary species.
3. List the case characteristics of cats for which these drugs are recommended.
4. Explain the potential adverse effects of SGLT2 inhibitors drugs in diabetic cats.
5. Identify the advantages and disadvantages of these drugs in diabetic cats and their contraindications.

**Pharmacy Technicians:**

1. Explain the mechanism of action of SGLT2 inhibitors in treatment of cats with type 2 diabetes mellitus.
2. Identify specific SGLT2 inhibitors that have been adequately evaluated in veterinary species.
3. List the case characteristics of cats for which these drugs are recommended.
4. Explain the potential adverse effects of SGLT2 inhibitors drugs in diabetic cats.
5. Identify the advantages and disadvantages of these drugs in diabetic cats and their contraindications.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-074-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699

2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224
<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Catherine Scott-Moncrief

Relevant financial disclosures: Dr. Scott-Moncrief reported receiving honorarium from Boehringer-Ingelheim, Idexx, & Elanco. All financial disclosures have been mitigated by our office.

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwheele4@uthsc.edu](mailto:jwheele4@uthsc.edu). The grievance will be reviewed,

and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions

## **CE Announcement**

Title – *Continuous Blood Glucose Monitoring in Dogs and Cats*

Date and Time of CE Activity – **July 13, 2024**

Location, including city and state – **Indianapolis, Indiana**

Overview – Pharmacists are asked to fill prescriptions for the use of CGM devices in dogs and cats but are not trained in their application or use in veterinary species. Pharmacists should be able to make recommendations for the application of appropriate devices and their applications in dogs and cats. The purpose of this lecture is to educate pharmacists and pharmacy technicians about the evidence supporting the use of these devices in dogs and cats. The role of these devices in monitoring diabetic dogs and cats will be discussed, and practical tips for application and maintenance of these devices will be provided. Case studies will be used to demonstrate their application. Troubleshooting guidance will be provided during the lecture and contraindications to use discussed.

Overall Activity Goal - The objective of this knowledge-based activity is to educate pharmacists and pharmacy technicians about the application of CGM in dogs and cats.

Target Audience – This activity is primarily intended for pharmacists and pharmacy technicians from all practice settings. No prerequisites required.

Learning Objectives – The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity.

Following completion of this activity, the participant should be able to:

### **Pharmacists:**

1. Explain the principles underlying the application of continuous glucose monitoring in veterinary species.
2. Identify devices that have been adequately evaluated in veterinary species.
3. List the indications for use of CGM devices in dogs and cats.
4. Explain reasons for CGM device failure.
5. Identify the advantages and disadvantages of these devices and their contraindications.



**Pharmacy Technicians:**

1. Identify devices that have been adequately evaluated in veterinary species.
2. List the indications for use of CGM devices in dogs and cats.
3. Explain reasons for CGM device failure.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hours of credit (0.1 CEU) and will be available within 30 days of activity completion. Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity via [utcop.learningexpressce.com](http://utcop.learningexpressce.com) within 14 days of the scheduled activity date. UAN: 0064-9999-24-075-L/H01-P/T. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Type of Activity: Knowledge

Fee Information: This is for the full program.

<b>ACVP &amp; ACA Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$599	\$699
2nd / 3rd Attendee	\$499	\$599
Technician/Resident	\$399	\$499
Student Pharmacist	\$199	\$224

<b>Non-Member Rates</b>	Early Bird through May 1, 2024	On-Time after May 1, 2024
1st Attendee	\$849	\$949
2nd / 3rd Attendee	\$749	\$849
Technician/Resident	\$474	\$574
Student Pharmacist	\$224	\$249

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Participating Faculty: Dr. Catherine Scott-Moncrief

Relevant financial disclosures: Dr. Scott-Moncrief reported receiving honorarium from Boehringer-Ingelheim, Idexx, & Elanco. All financial disclosures have been mitigated by our office.

How to earn credit – Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at [jwhee4@uthsc.edu](mailto:jwhee4@uthsc.edu). The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include: Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include: Processor and RAM requirements: single-core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.

Schedule:

Activity Overview and Goals

Presentation

Self-Assessment Activities

Discussion and Questions